(MedPage Today) — One dose of a bivalent or nonavalent human papillomavirus (HPV) vaccine was protective against HPV16 and HPV18 infections, and showed noninferiority to two doses, the randomized ESCUDDO trial found.
Among more than 20,000 girls…
Source link : https://www.medpagetoday.com/hematologyoncology/cervicalcancer/118816
Author :
Publish date : 2025-12-03 22:00:00
Copyright for syndicated content belongs to the linked Source.
